Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Eric Paul Winer, M.D.

TitleProfessor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Medical Oncology
450 Brookline Ave
Boston MA 02215
Phone617/632-6876
Fax617/632-1930

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan 1; 12(1):71-80.
    View in: PubMed
  2. Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women. Cancer. 2014 Jan 1; 120(1):20-5.
    View in: PubMed
  3. Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
    View in: PubMed
  4. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Reply to p.g. Tsoutsou et Al, o. Kaidar-person et Al, and a. Courdi et Al. J Clin Oncol. 2013 Dec 20; 31(36):4571-3.
    View in: PubMed
  5. Krop I, Winer EP. Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer. Clin Cancer Res. 2014 Jan 1; 20(1):15-20.
    View in: PubMed
  6. Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 Nov; 142(1):203-9.
    View in: PubMed
  7. Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.
    View in: PubMed
  8. Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH. Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer: A Cross-sectional Survey. Ann Intern Med. 2013 Sep 17; 159(6):373-81.
    View in: PubMed
  9. Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. Breast Cancer Res Treat. 2013 Sep; 141(2):255-9.
    View in: PubMed
  10. Metzger-Filho O, Winer EP, Krop I. Pertuzumab: Optimizing HER2 Blockade. Clin Cancer Res. 2013 Oct 15; 19(20):5552-6.
    View in: PubMed
  11. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24(9):2206-23.
    View in: PubMed
  12. Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
    View in: PubMed
  13. Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat. 2013 Jul; 140(2):331-9.
    View in: PubMed
  14. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
    View in: PubMed
  15. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013 Jul 20; 31(21):2692-8.
    View in: PubMed
  16. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. J Clin Oncol. 2013 Jul 1; 31(19):2382-7.
    View in: PubMed
  17. Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat. 2013 Jun; 139(2):607-16.
    View in: PubMed
  18. Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res. 2013 Oct; 48(5):1669-83.
    View in: PubMed
  19. Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
    View in: PubMed
  20. Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013 Jun; 22(3):203-10.
    View in: PubMed
  21. Ruddy KJ, Meyer ME, Giobbie-Hurder A, Emmons KM, Weeks JC, Winer EP, Partridge AH. Long-term risk perceptions of women with ductal carcinoma in situ. Oncologist. 2013; 18(4):362-8.
    View in: PubMed
  22. Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, Fornier M, Winer EP, Bunnell C, Krop IE. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 2013 Jul; 24(7):1841-7.
    View in: PubMed
  23. Seah DS, Scott SM, Najita J, Openshaw T, Krag K, Frank E, Sohl J, Stadler ZK, Garrett M, Silverman SG, Peppercorn J, Winer EP, Come SE, Lin NU. Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol. 2013 Jul; 24(7):1853-9.
    View in: PubMed
  24. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 2013 Jun; 24(6):1434-43.
    View in: PubMed
  25. Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):457-66.
    View in: PubMed
  26. Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
    View in: PubMed
  27. Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.
    View in: PubMed
  28. Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors. Breast. 2013 Apr; 22(2):197-9.
    View in: PubMed
  29. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
    View in: PubMed
  30. Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Res Treat. 2012 Dec; 136(3):919-26.
    View in: PubMed
  31. Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Kereakoglow S, Borges VF, Come SE, Schapira L, Winer EP, Partridge AH. Body image in recently diagnosed young women with early breast cancer. Psychooncology. 2013 Aug; 22(8):1849-55.
    View in: PubMed
  32. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012 Dec; 136(3):813-21.
    View in: PubMed
  33. Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol. 2013 Feb; 24(2):283-91.
    View in: PubMed
  34. Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.
    View in: PubMed
  35. Brooks JM, Chrischilles EA, Landrum MB, Wright KB, Fang G, Winer EP, Keating NL. Survival implications associated with variation in mastectomy rates for early-staged breast cancer. Int J Surg Oncol. 2012; 2012:127854.
    View in: PubMed
  36. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012 Aug; 26(8):688-94, 696.
    View in: PubMed
  37. Hudis CA, Citron ML, Muss H, Norton L, Winer EP. Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? J Clin Oncol. 2012 Sep 1; 30(25):3148-9; author reply 3149-50.
    View in: PubMed
  38. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
    View in: PubMed
  39. Keating NL, Kouri EM, He Y, West DW, Winer EP. Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis. Cancer. 2013 Jan 15; 119(2):250-8.
    View in: PubMed
  40. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6.
    View in: PubMed
  41. Bober SL, Giobbie-Hurder A, Emmons KM, Winer E, Partridge A. Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med. 2013 Feb; 10(2):370-7.
    View in: PubMed
  42. Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012 Aug 20; 30(24):2940-2.
    View in: PubMed
  43. Ligibel JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat. 2012 Aug; 134(3):1305-13.
    View in: PubMed
  44. Ruddy KJ, Pitcher BN, Archer LE, Cohen HJ, Winer EP, Hudis CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol. 2012 Dec; 23(12):3075-81.
    View in: PubMed
  45. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23.
    View in: PubMed
  46. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012 Sep 10; 30(26):3234-41.
    View in: PubMed
  47. Partridge AH, Ruddy KJ, Kennedy J, Winer EP. Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract. 2012 Sep; 8(5):e105-10.
    View in: PubMed
  48. Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82.
    View in: PubMed
  49. Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012; 17(6):775-82.
    View in: PubMed
  50. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov 15; 118(22):5463-72.
    View in: PubMed
  51. Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH. Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer. 2012 Apr; 12(2):119-26.
    View in: PubMed
  52. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun; 21(3):242-52.
    View in: PubMed
  53. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012 Jun; 133(3):1057-65.
    View in: PubMed
  54. Meropol NJ, Kris MG, Winer EP. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol. 2012 Mar 1; 30(7):690-1.
    View in: PubMed
  55. Krop I, Winer EP. Further progress in HER2-directed therapy. Lancet Oncol. 2012 Jan; 13(1):2-3.
    View in: PubMed
  56. Mayer EL, Gropper AB, Neville BA, Partridge AH, Cameron DB, Winer EP, Earle CC. Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol. 2012 Jan 10; 30(2):158-63.
    View in: PubMed
  57. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):1061-6.
    View in: PubMed
  58. Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.
    View in: PubMed
  59. Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers. Breast. 2011 Oct; 20 Suppl 3:S128-31.
    View in: PubMed
  60. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66.
    View in: PubMed
  61. Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(2):589-97.
    View in: PubMed
  62. Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a sentinel node biopsy be performed in patients with high-risk breast cancer? Int J Breast Cancer. 2011; 2011:973245.
    View in: PubMed
  63. Olson EM, Lin NU, Krop IE, Winer EP. The ethical use of mandatory research biopsies. Nat Rev Clin Oncol. 2011 Oct; 8(10):620-5.
    View in: PubMed
  64. Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 1; 29(28):3816-24.
    View in: PubMed
  65. Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, Sikov WM, Winer E, Mega AE. Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1075-80.
    View in: PubMed
  66. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32.
    View in: PubMed
  67. Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11.
    View in: PubMed
  68. Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011 Dec; 105(3):613-20.
    View in: PubMed
  69. Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011 Dec; 11(6):376-83.
    View in: PubMed
  70. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 1; 17(15):5170-8.
    View in: PubMed
  71. Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, Cohen HJ, Muss HB. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol. 2012 Mar; 23(3):632-8.
    View in: PubMed
  72. Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-7.
    View in: PubMed
  73. Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Ann Surg Oncol. 2011 Oct; 18(10):2885-92.
    View in: PubMed
  74. Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res. 2011 Jul; 39(12):4928-41.
    View in: PubMed
  75. Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9.
    View in: PubMed
  76. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
    View in: PubMed
  77. Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol. 2011 Mar 10; 29(8):1022-8.
    View in: PubMed
  78. Lin NU, Winer EP. Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. J Clin Oncol. 2011 Jan 20; 29(3):251-3.
    View in: PubMed
  79. Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011 Jan 1; 117(1):180-9.
    View in: PubMed
  80. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207.
    View in: PubMed
  81. Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011 Mar; 18(3):733-7.
    View in: PubMed
  82. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010 Dec; 7(12):683-92.
    View in: PubMed
  83. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010 Oct 1; 16(19):4702-10.
    View in: PubMed
  84. Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010 Sep-Oct; 17(5):908-16.
    View in: PubMed
  85. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104.
    View in: PubMed
  86. Ligibel JA, Partridge A, Giobbie-Hurder A, Campbell N, Shockro L, Salinardi T, Winer EP. Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer. J Womens Health (Larchmt). 2010 Aug; 19(8):1553-9.
    View in: PubMed
  87. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96.
    View in: PubMed
  88. Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Paskett EM, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010 Jul 7; 102(13):942-9.
    View in: PubMed
  89. Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol. 2010 Jul 1; 28(19):3146-53.
    View in: PubMed
  90. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8.
    View in: PubMed
  91. Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat. 2011 Feb; 125(3):803-13.
    View in: PubMed
  92. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10; 28(14):2418-22.
    View in: PubMed
  93. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010 Apr 7; 102(7):456-63.
    View in: PubMed
  94. de Moor JS, Partridge AH, Winer EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer. 2010 Mar 1; 116(5):1218-25.
    View in: PubMed
  95. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 1; 28(7):1145-53.
    View in: PubMed
  96. Freedman RA, Winer EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. Breast. 2010 Apr; 19(2):69-75.
    View in: PubMed
  97. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
    View in: PubMed
  98. Kouri EM, He Y, Winer EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Res Treat. 2010 Jun; 121(3):743-51.
    View in: PubMed
  99. Partridge AH, Winer EP. On mammography--more agreement than disagreement. N Engl J Med. 2009 Dec 24; 361(26):2499-501.
    View in: PubMed
  100. Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Dec 10; 27(35):6052-69.
    View in: PubMed
  101. Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
    View in: PubMed
  102. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 1; 27(34):5671-3.
    View in: PubMed
  103. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009 Oct; 133(10):1515-38.
    View in: PubMed
  104. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009 Sep 2; 101(17):1174-81.
    View in: PubMed
  105. Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care. 2009 Jul; 47(7):765-73.
    View in: PubMed
  106. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6.
    View in: PubMed
  107. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
    View in: PubMed
  108. Ligibel JA, Giobbie-Hurder A, Olenczuk D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control. 2009 Oct; 20(8):1523-8.
    View in: PubMed
  109. Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7.
    View in: PubMed
  110. Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.
    View in: PubMed
  111. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009; 2:11.
    View in: PubMed
  112. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009 Feb 15; 15(4):1452-9.
    View in: PubMed
  113. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44.
    View in: PubMed
  114. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
    View in: PubMed
  115. Partridge AH, Winer EP. Sharing study results with trial participants: time for action. J Clin Oncol. 2009 Feb 20; 27(6):838-9.
    View in: PubMed
  116. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009 Jan; 133(1):15-25.
    View in: PubMed
  117. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
    View in: PubMed
  118. Freedman RA, He Y, Winer EP, Keating NL. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):713-9.
    View in: PubMed
  119. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008 Dec 15; 14(24):8010-8.
    View in: PubMed
  120. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 1; 14(23):7871-7.
    View in: PubMed
  121. Freedman RA, Winer EP. Reducing disparities in breast cancer care: a daunting but essential responsibility. J Natl Cancer Inst. 2008 Dec 3; 100(23):1661-3.
    View in: PubMed
  122. Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000.
    View in: PubMed
  123. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov 15; 113(10):2638-45.
    View in: PubMed
  124. Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov; 17(11):1108-20.
    View in: PubMed
  125. Ligibel JA, Partridge A, Giobbie-Hurder A, Golshan M, Emmons K, Winer EP. Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ. Ann Surg Oncol. 2009 Jan; 16(1):106-12.
    View in: PubMed
  126. Winer E. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. Clin Adv Hematol Oncol. 2008 Aug; 6(8):573-4.
    View in: PubMed
  127. Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6.
    View in: PubMed
  128. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol. 2008 Jul; 36(7):755-68.
    View in: PubMed
  129. Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.
    View in: PubMed
  130. Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9.
    View in: PubMed
  131. Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E. Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer. 2008 Jun; 8(3):275-80.
    View in: PubMed
  132. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 1; 26(16):2659-65.
    View in: PubMed
  133. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
    View in: PubMed
  134. Krop IE, Winer EP. Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res Treat. 2009 Jan; 113(2):207-9.
    View in: PubMed
  135. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 7; 100(9):642-8.
    View in: PubMed
  136. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
    View in: PubMed
  137. Wong JS, Taghian AG, Bellon JR, Keshaviah A, Smith BL, Winer EP, Silver B, Harris JR. Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial. Int J Radiat Oncol Biol Phys. 2008 Nov 1; 72(3):866-70.
    View in: PubMed
  138. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1; 26(10):1642-9.
    View in: PubMed
  139. Lin NU, Winer EP. Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol. 2008 Apr 20; 26(12):1919-21.
    View in: PubMed
  140. Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008 Mar-Apr; 11(2):213-20.
    View in: PubMed
  141. Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C, Winer E. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90.
    View in: PubMed
  142. Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008 Feb 20; 26(6):907-12.
    View in: PubMed
  143. Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst. 2008 Feb 20; 100(4):243-51.
    View in: PubMed
  144. Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008 Feb 10; 26(5):696-7.
    View in: PubMed
  145. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9.
    View in: PubMed
  146. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008 Feb 10; 26(5):798-805.
    View in: PubMed
  147. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10; 26(8):1231-8.
    View in: PubMed
  148. Partridge AH, Gelber S, Peppercorn J, Ginsburg E, Sampson E, Rosenberg R, Przypyszny M, Winer EP. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008 Feb; 8(1):65-9.
    View in: PubMed
  149. Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 1; 112(3 Suppl):673-8.
    View in: PubMed
  150. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008 Feb 1; 112(3 Suppl):700-9.
    View in: PubMed
  151. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
    View in: PubMed
  152. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008 Feb 1; 26(4):556-62.
    View in: PubMed
  153. Razzak AR, Lin NU, Winer EP. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer. 2008; 15(1):31-4.
    View in: PubMed
  154. Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7.
    View in: PubMed
  155. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
    View in: PubMed
  156. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007 Nov 1; 96(6):474-80.
    View in: PubMed
  157. Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology. 2007 Dec; 245(3):824-30.
    View in: PubMed
  158. Winer EP, Harris JR, Smith BL, D'Alessandro HA, Brachtel EF. Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl J Med. 2007 Oct 18; 357(16):1640-8.
    View in: PubMed
  159. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Care in the months before death and hospice enrollment among older women with advanced breast cancer. J Gen Intern Med. 2008 Jan; 23(1):11-8.
    View in: PubMed
  160. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
    View in: PubMed
  161. Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903.
    View in: PubMed
  162. Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP. Sarcoidosis mimicking metastatic breast cancer. Clin Breast Cancer. 2007 Oct; 7(10):804-10.
    View in: PubMed
  163. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 1; 25(25):3797-9.
    View in: PubMed
  164. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 1; 110(5):965-72.
    View in: PubMed
  165. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007 Sep-Oct; 10(5):367-76.
    View in: PubMed
  166. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704.
    View in: PubMed
  167. Tolaney SM, Winer EP. Follow-up care of patients with breast cancer. Breast. 2007 Dec; 16 Suppl 2:S45-50.
    View in: PubMed
  168. Lin NU, Winer EP. Optimal use of aromatase inhibitors: to lead or to follow? J Clin Oncol. 2007 Jul 1; 25(19):2639-41.
    View in: PubMed
  169. Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007 Jun 7; 356(23):2399-405.
    View in: PubMed
  170. Berz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ. Cryopreservation of hematopoietic stem cells. Am J Hematol. 2007 Jun; 82(6):463-72.
    View in: PubMed
  171. Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10).
    View in: PubMed
  172. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007 Jul; 43(11):1646-53.
    View in: PubMed
  173. Ponte PR, Gross AH, Winer E, Connaughton MJ, Hassinger J. Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncol Nurs Forum. 2007 May; 34(3):611-6.
    View in: PubMed
  174. Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer. 2007 Apr 1; 109(7):1239-46.
    View in: PubMed
  175. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007 Mar 20; 25(9):1074-81.
    View in: PubMed
  176. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007 Mar 15; 13(6):1648-55.
    View in: PubMed
  177. Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
    View in: PubMed
  178. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312.
    View in: PubMed
  179. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
    View in: PubMed
  180. Wray RJ, Stryker JE, Winer E, Demetri G, Emmons KM. Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. J Cancer Educ. 2007; 22(1):21-4.
    View in: PubMed
  181. Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1.
    View in: PubMed
  182. Beck JG, Palyo SA, Winer EH, Schwagler BE, Ang EJ. Virtual Reality Exposure Therapy for PTSD symptoms after a road accident: an uncontrolled case series. Behav Ther. 2007 Mar; 38(1):39-48.
    View in: PubMed
  183. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006 Dec; 17(12):1777-82.
    View in: PubMed
  184. Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4.
    View in: PubMed
  185. Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E. Cancer-related communication between female patients and male partners scale: A pilot study. Psychooncology. 2006 Sep; 15(9):780-94.
    View in: PubMed
  186. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4.
    View in: PubMed
  187. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82.
    View in: PubMed
  188. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8.
    View in: PubMed
  189. Hayne CC, Winer E, Williams T, Chaves F, Khorsand J, Mark HF. Acute lymphoblastic leukemia with 4;11 translocation analyzed by a multi-modal strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the literature. Exp Mol Pathol. 2006 Aug; 81(1):62-71.
    View in: PubMed
  190. Hudis CA, Winer EP. Cancer and leukemia group B breast committee: decades of progress and plans for the future. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 2):3576s-80s.
    View in: PubMed
  191. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
    View in: PubMed
  192. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
    View in: PubMed
  193. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 1; 12(3 Pt 2):997s-1000s.
    View in: PubMed
  194. Bullitt E, Lin NU, Ewend MG, Zeng D, Winer EP, Carey LA, Smith JK. Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Med Image Comput Comput Assist Interv. 2006; 9(Pt 2):561-8.
    View in: PubMed
  195. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006 Jan 1; 24(1):85-94.
    View in: PubMed
  196. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66.
    View in: PubMed
  197. Ligibel JA, Winer EP. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer. Womens Health (Lond Engl). 2006 Jan; 2(1):89-97.
    View in: PubMed
  198. Lin NU, Gelman R, Winer EP. Dose density in breast cancer: a simple message? J Natl Cancer Inst. 2005 Dec 7; 97(23):1712-4.
    View in: PubMed
  199. Peppercorn J, Partridge A, Burstein HJ, Winer EP. Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8.
    View in: PubMed
  200. Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
    View in: PubMed
  201. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
    View in: PubMed
  202. Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res. 2005; 7(6):255-7.
    View in: PubMed
  203. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 1; 64(2):496-504.
    View in: PubMed
  204. Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006 Oct; 63(1-2):104-9.
    View in: PubMed
  205. Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15; 104(8):1580-9.
    View in: PubMed
  206. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20.
    View in: PubMed
  207. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7.
    View in: PubMed
  208. Krop IE, Winer EP. Ovarian suppression for breast cancer: an effective treatment in search of a home. J Clin Oncol. 2005 Sep 1; 23(25):5869-72.
    View in: PubMed
  209. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 1; 23(22):5178-87.
    View in: PubMed
  210. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89.
    View in: PubMed
  211. Hensley ML, Dowell J, Herndon JE, Winer E, Stark N, Weeks JC, Paskett E. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat. 2005 May; 91(2):153-61.
    View in: PubMed
  212. Partridge AH, Winer EP. Fertility after breast cancer: questions abound. J Clin Oncol. 2005 Jul 1; 23(19):4259-61.
    View in: PubMed
  213. Winer ES, Miller KB, Chan GW. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Oncology (Williston Park). 2005 Apr; 19(4 Suppl 2):11-4.
    View in: PubMed
  214. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol. 2005 Mar 10; 23(8):1609-10.
    View in: PubMed
  215. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 2; 293(9):1073-81.
    View in: PubMed
  216. Partridge AH, Wong JS, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop KL, Harris JR, Winer EP. Offering participants results of a clinical trial: sharing results of a negative study. Lancet. 2005 Mar 12-18; 365(9463):963-4.
    View in: PubMed
  217. Burstein HJ, Winer EP. HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 1; 23(16):3656-9.
    View in: PubMed
  218. Wittenberg E, Winer EP, Weeks JC. Patient utilities for advanced cancer: effect of current health on values. Med Care. 2005 Feb; 43(2):173-81.
    View in: PubMed
  219. Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005 Feb 1; 61(2):348-57.
    View in: PubMed
  220. Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med. 2005 Jan; 20(1):38-44.
    View in: PubMed
  221. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004 Dec; 31(6 Suppl 13):53-90.
    View in: PubMed
  222. Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 13):106-46.
    View in: PubMed
  223. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
    View in: PubMed
  224. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004 Oct 15; 22(20):4174-83.
    View in: PubMed
  225. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 2; 351(10):971-7.
    View in: PubMed
  226. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004 Sep 1; 22(17):3608-17.
    View in: PubMed
  227. Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004; 6(5):204-10.
    View in: PubMed
  228. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 1; 22(11):2061-8.
    View in: PubMed
  229. Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32.
    View in: PubMed
  230. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004 Mar 1; 22(5):854-63.
    View in: PubMed
  231. Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis. 2004; 21:55-64.
    View in: PubMed
  232. Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol. 2003 Dec 15; 21(24):4532-9.
    View in: PubMed
  233. Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25.
    View in: PubMed
  234. Schuchter L, Meropol NJ, Winer EP, Hensley ML, Somerfield MR. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol. 2003 Oct; 4(10):593.
    View in: PubMed
  235. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 1; 21(15):2889-95.
    View in: PubMed
  236. Bluman LG, Rimer BK, Regan Sterba K, Lancaster J, Clark S, Borstelmann N, Iglehart JD, Winer EP. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology. 2003 Jul-Aug; 12(5):410-27.
    View in: PubMed
  237. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
    View in: PubMed
  238. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.
    View in: PubMed
  239. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 1; 21(13):2597-9.
    View in: PubMed
  240. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51.
    View in: PubMed
  241. Ligibel JA, Winer EP. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. J Natl Compr Canc Netw. 2003 Apr; 1(2):215-21.
    View in: PubMed
  242. Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2.
    View in: PubMed
  243. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14.
    View in: PubMed
  244. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
    View in: PubMed
  245. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003 Feb 15; 21(4):602-6.
    View in: PubMed
  246. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
    View in: PubMed
  247. Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):473S-9S.
    View in: PubMed
  248. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 1; 21(1):46-53.
    View in: PubMed
  249. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99.
    View in: PubMed
  250. Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
    View in: PubMed
  251. DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):34S-8S.
    View in: PubMed
  252. Bunnell CA, Winer EP. Lumping versus splitting: the splitters take this round. J Clin Oncol. 2002 Sep 1; 20(17):3576-7.
    View in: PubMed
  253. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 1; 20(15):3328-43.
    View in: PubMed
  254. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 1; 20(15):3317-27.
    View in: PubMed
  255. Partridge AH, Winer EP. Informing clinical trial participants about study results. JAMA. 2002 Jul 17; 288(3):363-5.
    View in: PubMed
  256. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15; 20(12):2895-903.
    View in: PubMed
  257. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):38-43.
    View in: PubMed
  258. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002 May 1; 94(9):652-61.
    View in: PubMed
  259. Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105.
    View in: PubMed
  260. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 1; 94(1):25-36.
    View in: PubMed
  261. Burstein HJ, Bunnell CA, Winer EP. New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
    View in: PubMed
  262. Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 12):32-40.
    View in: PubMed
  263. Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med. 2001 Jul-Aug; 10(6):589-98.
    View in: PubMed
  264. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001 Jun 1; 19(11):2875-82.
    View in: PubMed
  265. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
    View in: PubMed
  266. Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001 May 1; 19(9):2381-9.
    View in: PubMed
  267. Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7.
    View in: PubMed
  268. Partridge AH, Bunnell CA, Winer EP. Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001; 14:41-50.
    View in: PubMed
  269. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42.
    View in: PubMed
  270. Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A. NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):33-49.
    View in: PubMed
  271. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94.
    View in: PubMed
  272. Partridge A, Winer E. Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years. Clin Breast Cancer. 2000 Jul; 1(2):164-5.
    View in: PubMed
  273. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000 Jul; 18(14):2710-7.
    View in: PubMed
  274. Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD. Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg. 2000 May; 231(5):624-34.
    View in: PubMed
  275. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
    View in: PubMed
  276. Speice J, Harkness J, Laneri H, Frankel R, Roter D, Kornblith AB, Ahles T, Winer E, Fleishman S, Luber P, Zevon M, McQuellon R, Trief P, Finkel J, Spira J, Greenberg D, Rowland J, Holland JC. Involving family members in cancer care: focus group considerations of patients and oncological providers. Psychooncology. 2000 Mar-Apr; 9(2):101-12.
    View in: PubMed
  277. Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000 Feb 15; 88(4):825-34.
    View in: PubMed
  278. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 Oct; 17(10):3333-55.
    View in: PubMed
  279. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
    View in: PubMed
  280. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 Aug; 17(8):2506-13.
    View in: PubMed
  281. Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73.
    View in: PubMed
  282. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
    View in: PubMed
  283. Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, White R, McGuirt C. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999 Apr; 10(4):397-402.
    View in: PubMed
  284. Marks LB, Hardenbergh PH, Winer ET, Prosnitz LR. Assessing the cost-effectiveness of postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999 Apr 1; 44(1):91-8.
    View in: PubMed
  285. Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6.
    View in: PubMed
  286. Winer EP, Lindley C, Hardee M, Sawyer WT, Brunatti C, Borstelmann NA, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psychooncology. 1999 Mar-Apr; 8(2):167-76.
    View in: PubMed
  287. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 1999 Jan; 17(1):52-63.
    View in: PubMed
  288. Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1999; 43(1):68-72.
    View in: PubMed
  289. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998 Oct-Dec; 18(4):365-75.
    View in: PubMed
  290. Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):39-43.
    View in: PubMed
  291. Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G, Winer EP. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer. 1998 Oct 1; 83(7):1362-8.
    View in: PubMed
  292. Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84.
    View in: PubMed
  293. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
    View in: PubMed
  294. Brown DM, Matise TC, Koike G, Simon JS, Winer ES, Zangen S, McLaughlin MG, Shiozawa M, Atkinson OS, Hudson JR, Chakravarti A, Lander ES, Jacob HJ. An integrated genetic linkage map of the laboratory rat. Mamm Genome. 1998 Jul; 9(7):521-30.
    View in: PubMed
  295. Thomason TE, McCune JS, Bernard SA, Winer EP, Tremont S, Lindley CM. Cancer pain survey: patient-centered issues in control. J Pain Symptom Manage. 1998 May; 15(5):275-84.
    View in: PubMed
  296. Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998 Apr; 16(4):1380-7.
    View in: PubMed
  297. Rimer BK, Sugarman J, Winer E, Bluman LG, Lerman C. Informed consent for BRCA1 and BRCA2 testing. Breast Dis. 1998 Apr; 10(1-2):99-114.
    View in: PubMed
  298. Tessaro I, Borstelmann N, Regan K, Rimer BK, Winer E. Genetic testing for susceptibility to breast cancer: findings from women's focus groups. J Womens Health. 1997 Jun; 6(3):317-27.
    View in: PubMed
  299. Demark-Wahnefried W, Hars V, Conaway MR, Havlin K, Rimer BK, McElveen G, Winer EP. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr. 1997 May; 65(5):1495-501.
    View in: PubMed
  300. Demark-Wahnefried W, Rimer BK, Winer EP. Weight gain in women diagnosed with breast cancer. J Am Diet Assoc. 1997 May; 97(5):519-26, 529; quiz 527-8.
    View in: PubMed
  301. Warmuth MA, Sutton LM, Winer EP. A review of hereditary breast cancer: from screening to risk factor modification. Am J Med. 1997 Apr; 102(4):407-15.
    View in: PubMed
  302. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 5; 89(3):227-38.
    View in: PubMed
  303. Sutton LM, Warmuth MA, Petros WP, Winer EP. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol. 1997; 40(4):335-41.
    View in: PubMed
  304. Fee-Fulkerson K, Conaway MR, Winer EP, Fulkerson CC, Rimer BK, Georgiade G. Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants. Plast Reconstr Surg. 1996 Jun; 97(7):1420-6.
    View in: PubMed
  305. Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother. 1996; 6(4):211-6.
    View in: PubMed
  306. Koike G, Winer ES, Horiuchi M, Brown DM, Szpirer C, Dzau VJ, Jacob HJ. Cloning, characterization, and genetic mapping of the rat type 2 angiotensin II receptor gene. Hypertension. 1995 Dec; 26(6 Pt 1):998-1002.
    View in: PubMed
  307. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct; 13(10):2567-74.
    View in: PubMed
  308. Otsen M, Den Bieman M, Winer ES, Jacob HJ, Szpirer J, Szpirer C, Bender K, Van Zutphen LF. Use of simple sequence length polymorphisms for genetic characterization of rat inbred strains. Mamm Genome. 1995 Sep; 6(9):595-601.
    View in: PubMed
  309. Pettersson A, Winer ES, Weksler-Zangen S, Lernmark A, Jacob HJ. Predictability of heterozygosity scores and polymorphism information content values for rat genetic markers. Mamm Genome. 1995 Aug; 6(8):512-20.
    View in: PubMed
  310. Winer EP, Chu L, Spicer DV. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9.
    View in: PubMed
  311. Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol. 1994 Sep; 12(9):1754-63.
    View in: PubMed
  312. Winer EP. Quality-of-life research in patients with breast cancer. Cancer. 1994 Jul 1; 74(1 Suppl):410-5.
    View in: PubMed
  313. Winer EP, Sutton LM. Quality of life after bone marrow transplantation. Oncology (Williston Park). 1994 Jan; 8(1):19-27; discussion 27-8, 31.
    View in: PubMed
  314. Winer EP, Fee-Fulkerson K, Fulkerson CC, Georgiade G, Catoe KE, Conaway M, Brunatti C, Holmes V, Rimer BK. Silicone controversy: a survey of women with breast cancer and silicone implants. J Natl Cancer Inst. 1993 Sep 1; 85(17):1407-11.
    View in: PubMed
  315. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1993 Jul; 11(7):1418-29.
    View in: PubMed
  316. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun; 11(6):1132-43.
    View in: PubMed
  317. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst. 1992 Dec 2; 84(23):1811-6.
    View in: PubMed
  318. Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JE, Trump DL. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res. 1992 May 1; 52(9):2456-9.
    View in: PubMed
  319. Brizel DM, Winer EP, Prosnitz LR, Scott J, Crawford J, Moore JO, Gockerman JP. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys. 1990 Sep; 19(3):535-42.
    View in: PubMed
  320. Rosenberg A, Winer EP, Cadman E. The use of adjuvant chemotherapy for breast cancer in a community practice. Conn Med. 1985 May; 49(5):281-5.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Winer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_